An international expanded access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

I Bodrogi; The REACT Study Group

An international expanded access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

I Bodrogi, The REACT Study Group

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Eur J Cancer
Publication status	Published - 29 Jul 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{94f53955fec8464dbd37800c21c0a20e,

title = "An international expanded access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy",

author = "V Grunwald and Karakiewicz PI and SE Bavbek and K. Miller and JP Machiels and SH Lee and J Larkin and L Bono and SY Rha and D Castellano and CU Blank and JJ Knox and Robert Hawkins and O Anak and M Rosamilia and J Booth and N Pirotta and I Bodrogi and {The REACT Study Group}",

year = "2011",

month = jul,

day = "29",

language = "English",

journal = "Eur J Cancer",

issn = "1879-0852",

publisher = "Elsevier BV",

}

An international expanded access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. / Bodrogi, I; The REACT Study Group.
In: Eur J Cancer, 29.07.2011.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - An international expanded access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

AU - Grunwald, V

AU - PI, Karakiewicz

AU - Bavbek, SE

AU - Miller, K.

AU - Machiels, JP

AU - Lee, SH

AU - Larkin, J

AU - Bono, L

AU - Rha, SY

AU - Castellano, D

AU - Blank, CU

AU - Knox, JJ

AU - Hawkins, Robert

AU - Anak, O

AU - Rosamilia, M

AU - Booth, J

AU - Pirotta, N

AU - Bodrogi, I

AU - The REACT Study Group

PY - 2011/7/29

Y1 - 2011/7/29

M3 - Article

SN - 1879-0852

JO - Eur J Cancer

JF - Eur J Cancer

ER -